Starboard Value Issues Presentation Delivered at 13D Monitor's 2024 Active-Passive Investor Summit

10/22/24 8:55:00 AM ET

$CRM

$KVUE

$PFE

Computer Software: Prepackaged Software

Technology

Specialty Chemicals

Consumer Discretionary

Get the next $CRM alert in real time by email

Starboard Value LP (together with its affiliates, "Starboard" or "we"), today announced that Jeffrey Smith, the firm's Chief Executive Officer and Chief Investment Officer, delivered a presentation at the 2024 Active-Passive Investor Summit to highlight value creation opportunities at three companies: Kenvue Inc. (NYSE:KVUE), Pfizer Inc. (NYSE:PFE) and Salesforce Inc. (NYSE:CRM). The full presentation and the respective presentations for the aforementioned companies can be found at: https://www.starboardvalue.com/presentations.

About Starboard Value LP

Starboard Value LP is an investment adviser with a focused and differentiated fundamental approach to investing in publicly traded companies. Starboard invests in deeply undervalued companies and actively engages with management teams and boards of directors to identify and execute on opportunities to unlock value for the benefit of all shareholders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241022671573/en/

Get the next $CRM alert in real time by email

Company	Date	Price Target	Rating	Analyst
Salesforce Inc. $CRM	11/19/2024	$425.00	Sector Outperform	Scotiabank
Pfizer Inc. $PFE	11/15/2024	$25.00	Underperform	Wolfe Research
Salesforce Inc. $CRM	11/15/2024	$305.00 → $385.00	Outperform	BMO Capital Markets
Pfizer Inc. $PFE	10/25/2024	$30.00	Neutral	Citigroup
Pfizer Inc. $PFE	10/17/2024	$32.00	Mkt Perform	Bernstein
Salesforce Inc. $CRM	10/2/2024	$400.00	Market Perform → Outperform	Northland Capital
Kenvue Inc. $KVUE	9/24/2024	$27.00	Buy	Jefferies
Kenvue Inc. $KVUE	9/24/2024	$24.00	Outperform → Sector Perform	RBC Capital Mkts

Starboard Value Issues Presentation Delivered at 13D Monitor's 2024 Active-Passive Investor Summit

Chat with this insight

Recent Analyst Ratings for $CRM$KVUE$PFE

$CRM$KVUE$PFE FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

October 25, 2024 - FDA Roundup: October 25, 2024

FDA Approval for HYMPAVZI issued to PFIZER INC

October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

$CRM$KVUE$PFE Financials

Live finance-specific insights

Salesforce Announces Timing of its Third Quarter Fiscal 2025 Results Conference Call

Kenvue Reports Third Quarter 2024 Results

Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance

$CRM$KVUE$PFE Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

Director Munoz Oscar bought $499,806 worth of shares (2,051 units at $243.69), increasing direct ownership by 41% to 7,026 units (SEC Form 4)

Morfit G Mason bought $99,796,760 worth of shares (428,000 units at $233.17) (SEC Form 4)

$CRM$KVUE$PFE Market Insights

Live Market Insights

European Commission Approves Pfizer's DURVEQTIX, A One-Time Gene Therapy For Adults With Hemophilia B

Pfizer's Options: A Look at What the Big Money is Thinking

Why ServiceNow Shares Are Rising Today

$CRM$KVUE$PFE Press Releases

Fastest customizable press release news feed in the world

$CRM$KVUE$PFE SEC Filings

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)

Salesforce Introduces Agentforce Testing Center: First-of-Its-Kind AI Agent Lifecycle Management Tooling for Testing Autonomous AI Agents at Scale

Fisher & Paykel Chooses Salesforce Agentforce to Boost Global Customer Sales and Service

SEC Form 10-Q filed by Kenvue Inc.

Kenvue Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Salesforce Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation

$CRM$KVUE$PFE Leadership Updates

Live Leadership Updates

Pfizer Announces New Chief Scientific Officer and President, Research & Development

Tim Buckley Elected to Pfizer's Board of Directors

Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

$CRM$KVUE$PFE Large Ownership Changes

This live feed shows all institutional transactions in real time.

$CRM$KVUE$PFE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

Amendment: SEC Form SC 13G/A filed by Salesforce Inc.

Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

Scotiabank initiated coverage on Salesforce with a new price target

Wolfe Research initiated coverage on Pfizer with a new price target

BMO Capital Markets reiterated coverage on Salesforce with a new price target

$CRM$KVUE$PFE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chairman & CEO Bourla Albert

SEC Form 4 filed by Executive Vice President Johnson Rady A

Co-Founder and CTO, Slack Harris Parker exercised 3,970 shares at a strike of $118.04 and sold $1,178,044 worth of shares (3,970 units at $296.74) (SEC Form 4)

Recent Analyst Ratings for
$CRM
$KVUE
$PFE

$CRM
$KVUE
$PFE
FDA approvals

$CRM
$KVUE
$PFE
Financials

$CRM
$KVUE
$PFE
Insider Purchases

$CRM
$KVUE
$PFE
Market Insights

$CRM
$KVUE
$PFE
Press Releases

$CRM
$KVUE
$PFE
SEC Filings

$CRM
$KVUE
$PFE
Leadership Updates

$CRM
$KVUE
$PFE
Large Ownership Changes

$CRM
$KVUE
$PFE
Analyst Ratings

$CRM
$KVUE
$PFE
Insider Trading